Cost-effectiveness analysis of captopril treatment after myocardial infarction
Le Pen, Claude; Lévy, Emile; Bonte, J. (1994), Cost-effectiveness analysis of captopril treatment after myocardial infarction, Archives des maladies du coeur et des vaisseaux, 87, 6, p. 775-781
TypeArticle accepté pour publication ou publié
Journal nameArchives des maladies du coeur et des vaisseaux
Société Française de Cardiologie
MetadataShow full item record
Author(s)Le Pen, Claude
Abstract (EN)The recently published "Survival and Ventricular Enlargement" (SAVE), prospective controlled trial over 4 years including over 2,000 patients, has shown that long-term treatment with captopril reduced cardiovascular mortality (- 19%) and morbidity in patients with post-infarction left ventricular dysfunction without signs of cardiac failure. Based on the trial data, the extra cost of treating the patients with captopril compared with the placebo branch is estimated at 9.3 million french francs. This expense is compensated by a reduction in the cost of hospitalisation for cardiac failure of 1.6 million francs and a reduction in the cost of further coronary events of 3.4 million francs. Above all, the extra cost is compensated by a gain of 47 deaths avoided, corresponding to about 493.5 years of life saved. The cost-effectiveness of captopril administration is therefore about 8.750 francs per year per life saved. The ratio is significantly less than that of other primary or secondary prevention therapeutic strategies. On this basis, we conclude that captopril therapy of high risk post-infarction patients is a solution that is not only medically effective but also economically sound.
Subjects / KeywordsCost of Medical care; Medical economics; Cost-benefit analysis
Showing items related by title and author.
Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France Chouaid, Christos; Bensimon, Lionel; Clay, Emilie; Millier, Aurélie; Levy-Bachelot, Laurie; Huang, Min; Lévy, Pierre (2019) Article accepté pour publication ou publié
Le Pen, Claude; Lévy, Emile; Ravily, V.; Beuzen, J.N.; Meurgey, F. (1994) Article accepté pour publication ou publié
Treatment of peritonitis in France: Comparative cost-effectiveness of the association imipenem-cilastatin and other antibiotic therapy Lévy, Emile; Lévy, Pierre (1993) Article accepté pour publication ou publié
The Economics of TRACE: A Cost-Effectiveness Analysis of Trandolapril in Postinfarction Patients with Left Ventricular Dysfunction Fiessinger, Sylvie; Keller, Thomas; Lilliu, Hervé; Le Pen, Claude (1998) Article accepté pour publication ou publié
PMH35 – Cost-Effectiveness of Paliperidone Palmitate Versus other Antipsychotics for the Treatment of Schizophrenia in France Doutriaux, Agathe; Cognet, Magali; Druais, Sylvain; Lançon, Christophe; Samalin, Ludovic; Lévy, Pierre; Godet, Annabelle; Guillon, Pascal (2014) Article accepté pour publication ou publié